On Air Now

Upcoming Shows

Program Schedule »

Tune in to Listen

1440 AM Green Bay, WI

Weather

Current Conditions(Green Bay,WI 54303)

More Weather »
75° Feels Like: 75°
Wind: SSE 9 mph Past 24 hrs - Precip: 0”
Current Radar for Zip

Tonight

Partly Cloudy 59°

Tomorrow

Partly Cloudy 78°

Sun Night

Thunderstorms Late 65°

Alerts

  • 0 Severe Weather Alerts
  • 0 Cancellations

GSK to partner with venture capital firm for drug discovery

Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. GlaxoSmithKline announce their half yearly
Signage is pictured on the company headquarters of GlaxoSmithKline in west London July 21, 2008. GlaxoSmithKline announce their half yearly

(Reuters) - GlaxoSmithKline said on Monday it will partner with venture capitalists Avalon Ventures in a deal worth up to $495 million to fund as many as 10 drug-discovery startup companies over the next three years.

GSK will provide financing and technical support to startups established by Avalon Ventures and will have first rights on buying each new company, GSK spokeswoman Melinda Stubbee said.

Avalon will contribute up to $30 million to the collaboration, and Glaxo will provide as much as $465 million in initial funding and development milestone payments, Stubbee said.

Big drugmakers see early-stage venture investing as a proxy for expensive in-house drug development, and some have set up their own venture funds.

Stubbee said each startup would have just a few employees, focusing on a single compound to develop treatments for conditions ranging from cancer to infectious diseases.

(Reporting by Susan Kelly in Chicago; Editing by Phil Berlowitz)

Comments